AstraZeneca enters a licensing agreement with Sino Biopharmaceutical covering a respiratory drug candidate for chronic obstructive pulmonary disease (COPD), according to reports. Under the deal, AstraZeneca pays Sino Biopharmaceutical $200 million upfront. Additional payments are structured around development and commercial milestones, with the total deal value reported at up to $1.9 billion. The disclosures emphasize the upfront consideration and the potential for further milestone-based payments, rather than changes to existing therapies or trial outcomes. The agreement reflects AstraZeneca’s focus on expanding its respiratory pipeline through external assets, while Sino Biopharmaceutical gains near-term funding tied to the licensed program’s progress. Terms beyond the disclosed payment structure, including timelines, geographic rights, and specific regulatory or commercial milestones, are not detailed in the provided excerpts. Overall, the sources agree on the key economic terms: the $200 million upfront payment and potential milestone payments bringing the deal’s value to as much as $1.9 billion.